A descriptive summary of the WHO availability assessments of medical abortion medicines in eight African countries

Table 1 Inclusion of MA medicines or protocols for their use in national policy documents

Country	MA medicines on NEML (Year)	Type of guideline that specifies MA protocols
Botswana	None (2012)	Comprehensive PAC Guideline & Trainer’s Manual, 2013
Burkina Faso	Mifepristone & Misoprostol (2020)	Reproductive Health Protocols, 2018
Central African Republic	Misoprostol (2017)^a	None
Democratic Republic of the Congo	Mifepristone & Misoprostol (2020)	Standards and Guidelines for Comprehensive Female-Centered Abortion Care, 2020
Eswatini	Misoprostol (2012)^b	None^c
Lesotho	Misoprostol (2017)	None
Namibia	Misoprostol (2021)	None
Uganda	Misoprostol (2016)	National Policy Guidelines & Service Standards for Sexual & Reproductive Health & Rights, 2nd Ed, 2012

^aIn Central African Republic misoprostol is listed for gastric ulcers only, whereas misoprostol is included for postpartum hemorrhage and PAC on all other NEML when listed
^bAt the time of the assessment, the Ministry of Health was revising the STG/EML. The Sexual and Reproductive Health Interagency Technical Coordinating Committee is advocating for the inclusion of WHO-approved regimens (misoprostol- alone and the combination regimen) for MA and the inclusion of misoprostol on the EML for all obstetric indications, including TOP
^cDraft Comprehensive Abortion Care Guidelines under development at the time of the assessment

ISSN: 1742-4755